Novonesis

400.60 DKK

+3.06 %

Less than 1K followers

NSIS B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

+3.06 %

+3.41 %

-1.28 %

-15.15 %

-1.74 %

-2.98 %

-6.38 %

+17.58 %

+982.70 %

Novonesis is a biochemistry company. The company develops enzymes and various microorganisms for industrial use. The enzymes are a protein used in a number of different industries, mainly in the agricultural and food industries. Novonesis products are used in various foods and clothing and the company holds sales on a global level. Novonesis was founded in 1921 and is headquartered in Bagsværd, Denmark.

Market cap

187.6B DKK

Turnover

312.2M DKK

Revenue

28.59B

EBIT %

13.07 %

P/E

80.17

Dividend yield-%

1.04 %

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

25/2

2026

Annual report '25

23/3

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press release11/21/2025, 9:47 AM

Trading by management and close relations of management

Regulatory press release11/7/2025, 3:39 PM

Trading by management and close relations of management

Regulatory press release11/7/2025, 9:34 AM

Major shareholder announcement

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/6/2025, 10:12 AM

Novonesis delivered 8% organic sales growth in the first nine months of 2025

Regulatory press release11/6/2025, 6:57 AM

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.

Regulatory press release11/4/2025, 2:11 PM

Trading by management and close relations of management

Regulatory press release9/10/2025, 12:09 PM

Major shareholder announcement

Regulatory press release9/2/2025, 10:57 AM

Trading by management and close relations of management

Regulatory press release8/28/2025, 10:19 AM

Amendment: Trading by management and close relations of management

Regulatory press release8/28/2025, 9:51 AM

Trading by management and close relations of management

Regulatory press release8/22/2025, 2:43 PM

Trading by management and close relations of management

Regulatory press release8/22/2025, 10:32 AM

Trading by management and close relations of management

Press release8/21/2025, 6:03 AM

Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%

Regulatory press release8/21/2025, 5:58 AM

Interim report H1 2025

Press release8/20/2025, 5:35 PM

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement

Regulatory press release8/20/2025, 3:45 PM

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement

Regulatory press release7/21/2025, 9:56 AM

Major shareholder announcement

Press release7/7/2025, 6:33 AM

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe

Regulatory press release6/30/2025, 4:59 PM

Transactions under Novonesis’ share buyback program

Regulatory press release6/23/2025, 1:31 PM

Transactions under Novonesis’ share buyback program

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.